Table 1.
Baseline data and effect of L-NAME treatment
| FENO (p.p.b) | ETCO2 (%) | MAP (mm Hg) | HR (bpm) | IP (cm H2O) | SaO2 (%) | PaCO2 (kPa) | pH | |
|---|---|---|---|---|---|---|---|---|
| Group 1a | ||||||||
| MPE 60 mg kg−1 (n=6) | ||||||||
| Baseline | 22±2 | 5.1±0.1 | 78±4 | 280±10 | 9.9±0.4 | 94±2 | 4.6±0.1 | 7.48±0.02 |
| Group 1b | ||||||||
| MPE 15 mg kg−1 (n=5) | ||||||||
| Baseline | 20±1 | 5.0±0.1 | 83±4 | 300±10 | 10.3±0.4 | 98±1 | 4.8±0.1 | 7.49±0.01 |
| Group 1c | ||||||||
| MPE 7.5 mg kg−1 (n=5) | ||||||||
| Baseline | 19±1 | 5.0±0.1 | 87±4 | 300±10 | 9.4±0.3 | 97±1 | 4.8±0.1 | 7.51±0.01 |
| Group 2a | ||||||||
| L-NAME+MPE 30 mg kg−1 (n=4) | ||||||||
| Baseline | 23±3 | 5.1±0.1 | 72±3 | 320±10 | 8.5±1.1 | 95±1 | 4.5±0.2 | 7.50±0.02 |
| After L-NAME | <1 | 4.9±0.1 | 91±7* | 310±10 | 8.8±1.0 | 95±1 | 4.4±0.1 | 7.50±0.03 |
| Group 2b | ||||||||
| L-NAME+MPE 15 mg kg−1 (n=6) | ||||||||
| Baseline | 18±1 | 4.9±0.1 | 81±2 | 310±20 | 7.5±1.2 | 96±1 | 4.5±0.1 | 7.51±0.01 |
| After L-NAME | <1 | 5.0±0.1 | 100±3** | 260±20* | 7.9±1.2 | 95±1 | 4.4±0.1 | 7.51±0.01 |
| Group 2c | ||||||||
| L-NAME+MPE 7.5 mg kg−1 (n=6) | ||||||||
| Baseline | 19±2 | 5.0±0.1 | 81±2 | 320±10 | 7.9±0.7 | 95±1 | 4.4±0.1 | 7.48±0.01 |
| After L-NAME | <1 | 4.9±0.1 | 95±4** | 320±20 | 8.0±0.7 | 94±1 | 4.3±0.1 | 7.49±0.01 |
Abbreviations: ETCO2, end-tidal carbon dioxide; FENO, nitric oxide concentration in mixed exhaled gas; HR, heart rate; IP, insufflation pressure; L-NAME, NG-nitro-L-arginine methyl ester; MAP, mean arterial blood pressure; MPE, muscle tissue pulmonary embolization; PaCO2, arterial partial pressure of carbon dioxide; SaO2, arterial oxygen saturation.
Artificially ventilated pentobarbital anesthetized rabbits. The table shows baseline values and the effects of L-NAME treatment (30 mg kg−1 i.v.) in different groups. * and ** indicate P<0.05 and P<0.01, respectively, when comparing values before and after L-NAME treatment.
*
P<0.05
**
P<0.01